Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation01:06

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Local delivery of lipid-based nanoparticles containing microbial nucleic acid for osteoimmunomodulation.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2025
Same author

Nanobody-liposomes as novel cancer vaccine platform to efficiently stimulate T cell immunity.

International journal of pharmaceutics·2024
Same author

Osteoimmunomodulatory GelMA/liposome coatings to promote bone regeneration of orthopedic implants.

Journal of controlled release : official journal of the Controlled Release Society·2023
Same author

Liposome induction of CD8<sup>+</sup> T cell responses depends on CD169<sup>+</sup> macrophages and Batf3-dependent dendritic cells and is enhanced by GM3 inclusion.

Journal of controlled release : official journal of the Controlled Release Society·2021
Same author

Port wine stain treatment outcomes have not improved over the past three decades.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019
Same author

A technical protocol for an experimental ex vivo model using arterially perfused porcine eyes.

Experimental eye research·2019

Related Experiment Video

Updated: May 23, 2026

A Comprehensive Approach to Analyze the Cell Components of Cerebral Blood Clots
06:12

A Comprehensive Approach to Analyze the Cell Components of Cerebral Blood Clots

Published on: July 21, 2023

[The white clot syndrome].

S Radke1, M Schwaberg, G Storm

  • 1Chirurgische Abteilung KH Altötting, Akademisches Lehrkrankenhaus der TU München.

Zentralblatt Fur Chirurgie
|April 3, 2012
PubMed
Summary

White clot syndrome, a rare heparin side effect, presents unique diagnostic and therapeutic challenges. Early recognition and management are crucial for patient outcomes.

Area of Science:

  • Hematology
  • Pharmacology
  • Pathophysiology

Background:

  • Routine anticoagulation with low-dose heparin is common for preventing thromboembolic events.
  • Heparin therapy can paradoxically trigger thrombotic complications in susceptible individuals.
  • Understanding heparin's complex effects on hemostasis is critical.

Observation:

  • White clot syndrome is an idiosyncratic adverse reaction to heparin.
  • This syndrome involves the formation of platelet-rich white clots.
  • Two distinct clinical presentations of white clot syndrome are described.

Findings:

  • Diagnosis relies on clinical suspicion and laboratory markers, often excluding other causes.
  • Therapeutic strategies include immediate heparin cessation and alternative anticoagulation.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

A Simple Protocol for Platelet-mediated Clumping of Plasmodium falciparum-infected Erythrocytes in a Resource Poor Setting
07:27

A Simple Protocol for Platelet-mediated Clumping of Plasmodium falciparum-infected Erythrocytes in a Resource Poor Setting

Published on: May 16, 2013

Related Experiment Videos

Last Updated: May 23, 2026

A Comprehensive Approach to Analyze the Cell Components of Cerebral Blood Clots
06:12

A Comprehensive Approach to Analyze the Cell Components of Cerebral Blood Clots

Published on: July 21, 2023

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

A Simple Protocol for Platelet-mediated Clumping of Plasmodium falciparum-infected Erythrocytes in a Resource Poor Setting
07:27

A Simple Protocol for Platelet-mediated Clumping of Plasmodium falciparum-infected Erythrocytes in a Resource Poor Setting

Published on: May 16, 2013

  • Prophylactic measures aim to identify and avoid heparin in high-risk patients.

    • Implications:

    • Highlights the need for vigilant monitoring during heparin therapy.
    • Informs clinical decision-making for managing heparin-induced thrombosis.
    • Emphasizes the importance of tailored anticoagulation strategies.